Caudate Glucose Metabolic Rate Changes with Both Drug and Behavior Therapy for Obsessive-Compulsive Disorder

Archives of General Psychiatry

Volumn 49, Issue 9, 1992, Pages 681-689

  Baxter, Lewis R ^a   Schwartz, Jeffrey M ^a   Bergman, Kenneth S ^a,b   Szuba, Martin P ^a   Guze, Barry H ^a   Mazziotta, John C ^a   Alazraki, Adina ^a,c   Selin, Carl E ^a   Ferng, Huan Kwang ^d   Munford, Paul ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d National Defense Medical Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOXETINE; GLUCOSE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HEMISPHERE; HUMAN; MALE; METABOLIC RATE; OBSESSION; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PUTAMEN; THALAMUS;

ADULT; BEHAVIOR THERAPY; CAUDATE NUCLEUS; CEREBRAL CORTEX; DEOXYGLUCOSE; FEMALE; FLUDEOXYGLUCOSE F 18; FLUOXETINE; GLUCOSE; GYRUS CINGULI; HUMAN; LATERALITY; MALE; OBSESSIVE-COMPULSIVE DISORDER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0026779811     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820090009002     Document Type: Article

References (79)

1. Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby-Year Book; 1990.
2. DeVeaugh-Geiss J. Pharmacologic treatment of obsessive-compulsive disorder. In: Zohar J, Insel T, Rasmussen S, eds. The Psychobiology of Obsessive-Compulsive Disorder. New York, NY: Springer Publishing Co Inc; 1991: 187–207.
3. Baer L, Minichiello WE. Behavior therapy for obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby-Year Book; 1990: 203–232.
4. Cummings JL, Frankel M. Gilles de la Tourette's syndrome and the neurological basis of obsessions and compulsions. Biol Psychiatry. 1985;20: 1117–1126.
5. Baxter LR, Phelps ME, Mazziotta JC, Guze GH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and normal controls. Arch Gen Psychiatry. 1987;44: 211–218.
6. Rapoport JL, Wise SP. Obsessive-compulsive disorder: is it a basal ganglia dysfunction? Psychopharmacol Bull. 1988;24: 380–384.
7. Modell JG, Mountx JM, Curtis GC, Greden JF. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry. 1989;1: 27–36.
8. Baxter LR, Schwartz JM, Guze BH, Bergman K, Szuba MP. Neuroimaging in obsessive-compulsive disorder: seeking the mediating neuroanatomy. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby-Year Book; 1990: 167–188.
9. Insel TR. Obsessive-compulsive disorder: a neuroethological perspective. Psychopharmacol Bull. 1988;24: 365–369.
10. Insel TR, Winslow JT. Neurobiology of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby-Year Book; 1990: 116–131.
11. Rapoport JL. Recent advances in obsessive-compulsive disorder. Neuropsychopharmacology. 1991;5: 1–10.
12. Phelps ME, Mazziotta JC. Positron emission tomography: human brain function and biochemistry. Science. 1985;228: 799–809.
13. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47: 926–932.
14. Turner SM, Jacob RG, Beidel DC, Himmelhoch J. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1985;5: 207–212.
15. Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland A. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1989;146: 909–911.
16. Benkelfat C, Nordahl TE, Semple WE, King C, Murphy DL, Cohen RM. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Arch Gen Psychiatry. 1990;47: 840–848.
17. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia. New York, NY: New York State Psychiatric Institute; 1978.
18. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46: 1006–1011.
19. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry. 1989;46: 1012–1016.
20. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Psychol. 1967;6: 278–296.
21. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry. 1969;3 (special issue): 76–79.
22. Schwartz JM, Martin K, Baxter LR. Neuroimaging and cognitivebehavioral self-treatment in obsessive-compulsive disorder: practical and philosophical considerations. In: Hand I, Goodman W, eds. Obsessive Compulsive Disorder: Recent Research. New York, NY: Springer-Verlag NY Inc. In press.
23. Mazziotta JC, Phelps ME, Miller J. Tomographic mapping of human cerebral metabolism: normal unstimulated state. Neurology. 1981;31: 503–516.
24. Barrio JR, MacDonald NS, Robinson GD, Najafi A, Cook JS, Kuhl DE. Remote, semiautomated production of F-18-labeled 2-deoxy-2-fluoro-Dglucose. J Nucl Med. 1981;22: 372–375.
25. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxyglucose: validation of method. Ann Neurol. 1979;6: 371–388.
26. Huang SC, Phelps ME, Hoffman SC, Sideris K, Selin CE, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980;238:E69-E82.
27. Mazziotta JC, Phelps ME, Meadors AK, Ricci A, Winter J, Bentson JR. Anatomical localization schemes for use in positron computed tomography using a specially designed headholder. J Comput Assist Tomogr. 1982;6: 848–853.
28. Cherry SR, Dahlbom M, Hoffman EJ. 3D PET using a conventional multislice tomograph without septa. J Comput Assist Tomogr. 1991;15: 655–668.
29. Reivich M, Alavi A, Wolf AP, Fowler J, Russell J, Arnett C, Mac-Gregor RR, Shiue CY, Atkins H, Anaud A, Dahn R, Greenberg JH. Glucose metabolic rate kinetic model parameter determination in man: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab. 1985;5: 179–192.
30. Brooks RA, Hatazawa J, Di Chiro G, Larson SM, Fishbein DS. Human cerebral glucose metabolism determined by positron emission tomography: a revisit. J Cereb Blood Flow Metab. 1987;7: 427–432.
31. Reivich M, Kuhl D, Wolf A, Greenberg JH, Phelps ME, Ido T, Cassel la V, Fowler J, Hoffman EJ, Alvani A, Sokoloff L. The [18F]fluorodeoxy-glucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44: 127–137.
32. Mazziotta JC, Phellps ME, Plummer D. Optimization and standardization of anatomical data in neurobehavioral investigations using positron CT. J Cereb Blood Flow Metab. 1983;3(suppl):S266-S267.
33. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland RP, Rapoport SI, Rapoport JL. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 1989;46: 518–523.
34. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry. In press.
35. Hayes WL. Statistics. New York, NY: Holt Rinehart & Winston; 1963.
36. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48: 730–738.
37. Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Meissner M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab. 1988;8: 502–512.
38. Bartlett EJ, Barouche F, Brodie JD, Wolkin A, Angrist B, Rotrosen J, Wolf AP. The stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res. 1991;40: 11–20.
39. Austin LS, Lydiard RB, Ballenger JC, Cohen BM, Laraia MT, Zealberg JJ, Fossey MD, Ellinwood EH. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;30: 225–232.
40. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987;22: 667–687.
41. Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50: 339–342.
42. Hollander E, Schiffman E, Cohen B, Rivera-Stein MA, Rosen W, Gorman JM, Fyer AJ, Papp L, Liebowitz MR. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47: 27–32.
43. Mazziotta JC, Grafton ST, Woods RC. The human motor system studied with PET measurements of cerebral blood flow: topography and motor learning. In: Lassen NA, Ingvar DH, Raichle ME, Frieberg L, eds. Brain Work and Mental Activity: Quantitative Studies With Radioactive Tracers: Proceedings of the 31st Alfred Benzon Symposium. Copenhagen, Denmark: Munksgaard; 1991: 280–293.
44. Baxter LR, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, Sumida RM. Cerebral metabolic rates for glucose in mood disorders: atudies with positron emission tomography and 18F-fluorodeoxyglucose. Arch Gen Psychiatry. 1985;42: 441–447.
45. Mavissakalian M, Michelson L. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? J Nerv Ment Dis. 1983;171: 301–306.
46. Fogelson DL, Bystritsky S. Imipramine in the treatment of OCD with and without major depression. Ann Clin Psychiatry. 1991;3: 233–237.
47. Penney JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci. 1983;6: 73–94.
48. Villablanca JR, Olmstead CE. The striatum: a finer tuner of the brain. Acta Neurobiol Exp (Warsz). 1982;42: 227–299.
49. Baxter LR, Mazziotta JC, Pahl JJ, Grafton ST. St George-Hyslop P, Haines JL, Gusella J, Szuba MP, Selin CE, Guze BH, Phelps ME. Psychiatric, genetic and PET evaluation of persons at-risk for Huntington's disease. Arch Gen Psychiatry. 1992;49: 148–154.
50. Phillips AG, Carr GD. Cognition and the basal ganglia: a possible substrate for procedural knowledge. Can J Neurol Sci. 1987;14: 381–385.
51. Packard MG, Hirsh R, White NM. Differential effects of fornix and caudate nucleus lesions on two radial maze tasks: evidence for multiple memory systems. J Neurosci. 1989;9: 1465–1472.
52. Mittleman G, Whishaw IQ, Jones GH, Koch M, Robbins TW. Cortical, hippocampal and striatal mediation of schedule-induced behaviors. Behav Neurosci. 1990;104: 399–409.
53. Packard MG, White NM. Lesions of the caudate nucleus selectively impair ‘reference memory’ acquisions in the radial maze. Behav Neural Biol. 1990;53: 39–50.
54. Swedo SE, Rapoport JL, Cheslow DL, Leonard HL, Ayoub EM, Hosier DM, Wald ER. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989;146: 246–249.
55. Mazziotta JC, Phelps ME. Positron emission tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert HR, eds. Positron Emission Tomography and Autoradiography. New York, NY: Raven Press; 1986.
56. Baxter LR, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145: 1560–1563.
57. Nordhal TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 1989;2: 23–28.
58. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12: 366–375.
59. Rapoport JL, Ryland DH, Kriete M. Drug treatment of canine acral lick: an animal model of obsessive-compulsive disorder. Arch Gen Psychiatry. In press.
60. Jenike MA, Bear L, Ballantine HT, Martuza RL, Tynes S, Giriunas I, Buttolph L, Cassem NH. Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 patients. Arch Gen Psychiatry. 1991;48: 548–555.
61. Greybiel AM, Ragsdale CW. Biochemical anatomy of the striatum. In: Emson PC. Chemical Neuroanatomy. New York, NY: Raven Press; 1983: 427–504.
62. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RSJ. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990;47: 1290–1298.
63. Grome JJ, Harper AM. Local cerebral glucose utilization following indoleamine- and piperazine-containing 5-hydroxytryptamine agonists. J Neurochem. 1986;46: 117–124.
64. Leonard HL, Swedo SE, Koby EV, Rapoport JL, Lengne MC, Cheslow DL, Hamburger SD. Treatment of obsessive-compulsive disorder with clomipramine and desmethylimipramine in children and adolescents: a doubleblind crossover comparison. Arch Gen Psychiatry. 1989;46: 1088–1092.
65. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;47: 577–585.
66. Kandel ER. Genes, nerve cells, and the remembrance of things past. J Neuropsychiatry. 1989;1: 103–125.
67. Montarolo PG, Goelet P, Castellucci VF, Morgan J, Kandel ER, Schacher S. A critical period for macromolecular synthesis in longterm heterosynaptic facilitation in Aplysia. Science. 1986;234: 1249–1254.
68. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46: 971–982.
69. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mal linger AG, Thase ME, McEachran AB, Grochocinsky VJ. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47: 1093–1099.
70. Klerman GL. Treatment of recurrent unipolar major depressive disorder: commentary on the Pittsburgh study. Arch Gen Psychiatry. 1990;47: 1158–1162.
71. Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry. 1986;47: 117–122.
72. Mavissakalian M. Imipramine in agoraphobia. Compr Psychiatry. 1986;27: 401–406.
73. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45: 413–422.
74. Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, Stern RS. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry. 1983;40: 153–162.
75. Salkovskis PM, Jones DRO, Clark DM. Respiratory control in the treatment of panic attacks: replications. Br J Psychiatry. 1986;148: 526–532.
76. Baxter LR. PET studies of cerebral function in major depression and obsessive-compulsive disorder: the emerging prefrontal cortex consensus. Ann Clin Psychiatry. 1991;3: 103–109.
77. Reiman EM, Raichel ME, Butler FK, Herscovitch P, Robins E. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature. 1984;310: 683–685.
78. Reiman EM, Raichle ME, Robins E, Minton MA, Fusselman MJ, Fox PT, Price JL, Hackman KA. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry. 1989;46: 493–500.
79. Nordahl TE, Semple WE, Gross M, Mellman TA, Stein MB, Goyer P, King AC, Uhde TW, Cohen RM. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology. 1990;3: 261–272.